Physician profile
Sandra E Voge
NPI 1598739674
$2,032.80
in general payments reported to CMS, 2019-2025
19 companies · $699 in 2025
The $699 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.99 · 2022: $309 · 2023: $409 · 2024: $561 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $343.10 | 2023-2025 | Veklury, Epclusa |
| Abbvie INC. | $301.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $170.06 | 2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $157.21 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2022 | |
| Novo Nordisk INC | $120.93 | 2024-2025 | Ozempic, Wegovy |
| Scynexis, INC. | $112.90 | 2022 | |
| Lilly USA, LLC | $111.66 | 2025 | Omvoh |
| Pfizer INC. | $93.49 | 2023 | |
| Janssen Biotech, INC. | $75.49 | 2024-2025 | Tremfya, Simponi, Stelara |
| Otsuka America Pharmaceutical, INC. | $71.54 | 2022 | |
| Glaxosmithkline, LLC. | $69.23 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.34 | 2024-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $55.52 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.24 | 2025 | Xifaxan, Relistor |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $51.91 | 2025 | Rezdiffra |
| Qol Medical, LLC | $25.24 | 2025 | Sucraid |
| Evoke Pharma, INC. | $17.07 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $15.17 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Voge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.